{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:35Z","timestamp":1790913335395,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3318,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Neurol."],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1002\/ana.20936","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T23:40:15Z","timestamp":1153525215000},"page":"243-247","source":"Crossref","is-referenced-by-count":62,"title":["Proteasome inhibitor-induced model of Parkinson's disease"],"prefix":"10.1002","volume":"60","author":[{"given":"Kevin St. P.","family":"McNaught","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Warren","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1002\/ana.20936-BIB1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","article-title":"Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease","volume":"56","author":"McNaught","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB2","first-page":"P80","article-title":"PSI induces proteasome inhibition and motor disturbances in rats","volume":"21","author":"Thomas","year":"2006","journal-title":"Mov Disord"},{"key":"10.1002\/ana.20936-BIB3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.20932","article-title":"Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats","volume":"60","author":"Zeng","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.20934","article-title":"Proteosomal inhibition causes loss of nigral tyrosine hydroxylase neurons","volume":"60","author":"Schapira","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.20938","article-title":"Lack of nigrostriatal pathology in a rat model of proteosome inhibition","volume":"60","author":"Manning-Bog\u0306","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ana.20937","article-title":"Proteasome inhibition and Parkinson's disease modeling","volume":"60","author":"Bov\u00e9","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.20935","article-title":"Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ana.20939","article-title":"The proteosomal inhibition model of Parkinson's disease: \u201cboon or bust\u201d?","volume":"60","author":"Lang","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1002\/ana.20936-BIB9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0140-6736(04)16901-8","article-title":"Pathogenetic mechanisms of parkin in Parkinson's disease","volume":"364","author":"Hattori","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/ana.20936-BIB10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neurobiolaging.2005.08.012","article-title":"Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease","volume":"25","author":"McNaught","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1002\/ana.20936-BIB11","first-page":"55","article-title":"Molecular pathophysiology of Parkinson's disease","volume":"25","author":"Moore","year":"2005","journal-title":"Annu Rev Neurosci"},{"key":"10.1002\/ana.20936-BIB12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in sporadic Parkinson's disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1002\/ana.20936-BIB13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson's disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1002\/ana.20936-BIB14","doi-asserted-by":"crossref","first-page":"44405","DOI":"10.1074\/jbc.M308041200","article-title":"Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function","volume":"278","author":"Tofaris","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1002\/ana.20936-BIB15","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1046\/j.1460-9568.2002.02301.x","article-title":"Aggresome-related biogenesis of Lewy bodies","volume":"16","author":"McNaught","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1002\/ana.20936-BIB16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1471-4159.2002.00821.x","article-title":"Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures","volume":"81","author":"McNaught","year":"2002","journal-title":"J Neurochem"},{"key":"10.1002\/ana.20936-BIB17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0896-6273(02)01125-X","article-title":"Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons","volume":"36","author":"Petrucelli","year":"2002","journal-title":"Neuron"},{"key":"10.1002\/ana.20936-BIB18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1471-4159.2005.03124.x","article-title":"Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP, following proteasomal inhibition","volume":"93","author":"Rideout","year":"2005","journal-title":"J Neurochem"},{"key":"10.1002\/ana.20936-BIB19","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","article-title":"Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition","volume":"23","author":"Fornai","year":"2003","journal-title":"J Neurosci"},{"key":"10.1002\/ana.20936-BIB20","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00001756-200208070-00018","article-title":"Proteasome inhibition causes nigral degeneration with inclusion bodies in rats","volume":"13","author":"McNaught","year":"2002","journal-title":"NeuroReport"},{"key":"10.1002\/ana.20936-BIB21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2005.01.024","article-title":"Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition","volume":"380","author":"Miwa","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1002\/ana.20936-BIB22","first-page":"LB","article-title":"Proteasome inhibitors cause a progressive model of Parkinson's disease in mice","volume":"20","author":"Nair","year":"2005","journal-title":"Mov Disord"},{"key":"10.1002\/ana.20936-BIB23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000066623","article-title":"Participation of the 26S proteasome in the regulation of progesterone receptor concentrations in the rat brain","volume":"76","author":"Camacho-Arroyo","year":"2002","journal-title":"Neuroendocrinology"},{"key":"10.1002\/ana.20936-BIB24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem Biol"}],"updated-by":[{"DOI":"10.1002\/ana.21662","type":"correction","label":"Correction","source":"retraction-watch","updated":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T00:00:00Z","timestamp":1237507200000},"record-id":"5922"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.20936","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ana.20936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T14:18:53Z","timestamp":1625149133000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.20936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"URL":"https:\/\/doi.org\/10.1002\/ana.20936","relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}